Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Peter Horby and Frederick Hayden.
Peter Horby
Connection Strength
0.352
Frederick Hayden
  1. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine. 2020 Dec; 62:103125.
    View in: PubMed
    Score: 0.057
  2. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Front Med. 2020 Oct; 14(5):601-612.
    View in: PubMed
    Score: 0.056
  3. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. 2020 May 24; 21(1):422.
    View in: PubMed
    Score: 0.055
  4. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 05 16; 395(10236):1569-1578.
    View in: PubMed
    Score: 0.055
  5. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 05 07; 382(19):1787-1799.
    View in: PubMed
    Score: 0.055
  6. A novel coronavirus outbreak of global health concern. Lancet. 2020 02 15; 395(10223):470-473.
    View in: PubMed
    Score: 0.054
  7. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006 Jan; 12(1):81-7.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.